|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Luminal A was the most common subtype (67.7%), luminal B was observed in 26.5% of the cases and HER2 positive and triple negative were represented by 2.1% and 3.7% of tumors, respectively.
|
22527108 |
2012 |
|
Luminal B Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
According to the immunohistochemical results, 35.3 % of the study cases were considered as Luminal B (LumB: either being higly proliferative or co-expressing HER2) and 33.3 % as triple negative breast carcinomas (TNBC).
|
23709114 |
2013 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The median methylation levels of the secreted frizzled-related protein 1 (SFRP1) gene were significantly lower in the basal-like subtype compared to the luminal A, luminal B and human epidermal growth factor receptor 2 (HER2) subtypes.
|
23467623 |
2013 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In BC, the classification of tumors as either ERα+ (Luminal A and Luminal B), HER2+ (ERα+ or ERα-) or triple-negative (TNBC)(Basal-like, claudin-low) guides both prognostication and therapy.
|
23945331 |
2013 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with Basal (90), HER2 (119), Luminal B (98) and Luminal A (76) tumor subtypes had a median TPDBM of 27.5, 35.8, 47.4 and 54.4 months (p < 0.01), median survival from PD of 39.6, 66.4, 90.3 and 72.7 months (p < 0.01) and median survival from BM of 7.3, 17.9, 22.9 and 10.0 months (p < 0.01), respectively.
|
23462853 |
2013 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results remain after multivariate adjustment, showing weekly administration was more effective in the luminal-B (HER2-positive) subgroup (p = .02) but not in the ERBB2+ subgroup (p = .50).
|
23635560 |
2013 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, gene expression profiling enabled the classification of breast cancers into four main subtypes - basal-like, HER2+ (human epidermal growth factor receptor 2-positive), luminal A and luminal B - and this classification is used to direct the use of targeted therapies such as tamoxifen or trastuzumab.
|
23680167 |
2013 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty kinds of miRNAs were homogenously distributed in the tumors from different clinicopathological subtypes that included 6 kinds of miRNAs in Luminal B Ki67+ and Luminal B Her2+ subtypes, 1 kind in Luminal B Ki67+ and Her2 overexpression subtypes, 10 kinds between Luminal B Ki67+ and TNBC subtypes, 2 kinds in Luminal B Her2+ and TNBC subtypes, and 1 kind between Luminal B Ki67+, Luminal B Her2+, and TNBC subtypes.
|
23803104 |
2013 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that 1) the luminal group (luminal A and luminal B) are clustered together, as well as the basal group (basal-like and HER2+) and 2) luminal A and luminal B are more close to each other than basal-like and HER2+ to each other.
|
23369492 |
2013 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared to luminal A tumors (93.4%), luminal B (80.8%), HER-2-positive (71.4%) and triple-negative (76.9%) tumors exhibited a reduced disease-free survival (DFS).
|
23709349 |
2013 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Disease free survival rate in the HER-2 positive groups (luminal B and HER-2 enriched) was worse than the HER-2 negative groups (luminal A and triple negative).
|
24289582 |
2013 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRMS1 rs3116068 was associated with increased likelihood of having the luminal B and the HER2-enriched tumor subtype (P trend = 0.03).
|
23771732 |
2013 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In view of the current knowledge, the following have been significantly more often observed: mammographical spiculated mass with echogenic halo in luminal A sub-type; architectural distortion in luminal B sub-type; an irregular mass with indistinct margin comprising microcalcifications, with an abrupt interface in the sonography, or non-sonographic mass in the HER2 sub-type; a very hypoechogenic, lobulated mass with indistinct or microlobulated margin, with an abrupt interface, sometimes pseudo-benign, in the triple-negative sub-type.
|
24508482 |
2014 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, HR of breast cancer death varied over time [<5 years (early) vs. > 5 years (late)] for both Basal-like (HR, 6.23 early vs. HR, 0.63 late) and HER2-E tumors (HR, 2.97 early vs. HR, 0.73 late) but not for LumB tumors where risk was elevated consistently (HR, 2.67 early vs. HR, 1.47 late).
|
24521998 |
2014 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The subtypes based on immunohistochemical staining were 60 cases of luminal A (LA) type (23.2%), 37 cases of luminal B (LB) (HER2-) type (14.3%), 91 cases of LB (HER2+) type (35.1%), 40 cases of human epidermal growth factor receptor 2 (HER2) type (15.4%) and 31 cases of triple negative (TN) type (12%).
|
22467403 |
2014 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
No significant change in luminal-A (n = 46), luminal-B (n = 85) and luminal-B HER2-positive (n = 24) tumors was observed.
|
24351403 |
2014 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IHC molecular subtypes were defined based on expression of these markers: Luminal A: ER+ and/or PR+, HER2- and Ki67-; Luminal B: ER+ and/or PR+ and ki67+; ERBB2: ER-, PR- and HER2+; Basal-like: ER-, PR-, HER2- and EGFR+ and/or CK5/6+; Unclassified: ER-, PR-, HER2-, EGFR- and CK5/6-.
|
24767310 |
2014 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To examine the utility of Ki67 in assignment of immunohistochemically molecular subtypes, cases were assigned into Luminal A (ER-positive, HER2-negative, Ki67 ≤14%), Luminal B (ER-positive, HER2-negative, Ki67 >14%) and triple negative (ER/PR-negative and HER2-negative, any Ki67).
|
24403187 |
2014 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We obtained stored tumor tissue from incident breast cancers and used immunohistochemistry and in situ hybridization to classify 825 invasive tumors into three luminal subtypes [Luminal A, Luminal B (HER2-) and Luminal B (HER2+)] and three non-luminal subtypes [human epidermal growth factor receptor 2 (HER2) subtype, basal-like phenotype (BP) and five negative phenotype (5NP)].
|
24789514 |
2014 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The distribution of subtypes was: Luminal A, 28.3% (n=30); Luminal B, 31.1% (n=33); HER2-like, 24.5% (n=26); and basal like/ triple negative (BL/TN), 16.0% (n=17).
|
25422228 |
2014 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Classical morphological parameters, such as lobular histotype and inflammation, confirmed their predictive value in response to NAC, particularly in the Luminal B/HER2- subgroup, which is a challenging breast cancer subtype from a therapeutic point of view.
|
25395316 |
2014 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RNA from 270 patients was evaluable; 84 patients (31%) were classified as luminal A, 97 (36%) luminal B, 43 (16%) basal-like, and 46 (17%) as HER2-enriched.
|
24359601 |
2014 |
|
Luminal B Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further analysis showed that OS, RFS, and DFS were similar between ILC and IDC patients in the subgroups of luminal A and triple-negative BC with HER2 negativity but were worse in ILC patients than those in IDC patients in the subgroups of luminal B and HER2 overexpression with positive HER2 expression.
|
25804795 |
2015 |
|
Luminal B Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Alteration of p16 was the highest in the luminal B and HER-2 groups, and pRB expression rate was the highest in the HER-2 group and lowest in the luminal A group.
|
26339389 |
2015 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 5-year BCFIs by subtype were luminal B-HER2 (+), 94.2 %; luminal A, 93.9 %; luminal B-HER2 (-), 91.4 %; HER2, 83.1 %; and triple-negative, 81.9 % (p < 0.001).
|
25893592 |
2015 |